Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 9/20 | 0.52 |
| ▸ | CCR3 | P51677 | 9/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462103 | 0.95 | GPR119 (0.58) | GPR119HRH3CHEK2HRH1CCR3 | |
| SCHEMBL4720822 | 0.93 | HRH1 (0.62) | GPR119HRH3HRH1CCR3KCNH2 | |
| SCHEMBL4140781 | 0.90 | HRH1 (0.64) | HRH1CCR3KCNH2 | |
| SCHEMBL20570284 | 0.90 | GPR119 (0.57) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL5459344 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL3091210 | 0.89 | GPR119 (0.64) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL20570922 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL214556 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL30272608 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL15536283 | 0.89 | GPR119 (0.67) | GPR119HRH3CHEK2NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1493743-B1 | Substituted bipiperidine intermediates and derivatives thereof | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | disclosed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | GPR119 1034/4885HRH3 17/4885CHEK2 4389/4885 |
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | GPR119 164/4885HRH3 339/4885CHEK2 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.